GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $62,567,484 | $55,250,629 | $62,463,606 |
| - Cash | – | $3,296,000 | $3,599,000 | $4,464,000 |
| + Debt | – | $17,750,000 | $0 | $18,432,000 |
| Enterprise Value | – | $77,021,484 | $51,651,629 | $76,431,606 |
| Revenue | $8,547,000 | – | $7,986,000 | $7,516,000 |
| % Growth | – | – | 6.3% | – |
| Gross Profit | $6,289,000 | – | $5,821,000 | $5,579,000 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| EBITDA | $3,361,000 | – | $3,230,000 | $3,093,000 |
| % Margin | 39.3% | – | 40.4% | 41.2% |
| Net Income | $2,013,000 | – | $1,443,000 | $1,624,000 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| % Growth | – | – | -10.3% | – |
| Operating Cash Flow | $3,027,581 | – | $2,096,000 | $1,145,000 |
| Capital Expenditures | -$428,373 | – | -$633,000 | -$448,000 |
| Free Cash Flow | $2,599,208 | – | $1,463,000 | $697,000 |